Drug intelligence / Profile preview

MK-4318

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-4318 is an orally administered small molecule therapeutic under development by Merck Sharp & Dohme for the treatment of pain. Its precise mechanism of action has not been disclosed, and it is considered to have a non-novel mechanism. The drug has reached Phase 1 clinical trials, where its pharmacokinetics and safety profile are being evaluated, including in combination with diltiazem in healthy volunteers. As of early 2025, there are no approved indications or known adverse events reported for MK-4318.

Beyond the preview

Go deeper on MK-4318.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-4318.

Explore the full profile